

Application No.: 10/669403  
Docket No.: UC0315USNA

Page 6

### REMARKS

The above amendments and below remarks are responsive to the Office communication dated, October 20, 2005, wherein the Examiner rejected Claim 15 (as previously amended) and allowed Claim 20.

The pending claims are Claims 15, 22, and 23.

Claim 15 is not amended and arguments for its novelty are provided below. New Claim 23 is directed to much of the same subject matter as that of Claim 15, however, "X" has been narrowed from that recited for Claim 15 to recite that which is as illustrated below using the strikethrough designations:

X is H, F, Cl, Br, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> alkoxy C<sub>1</sub>-C<sub>10</sub> oxyalkyl, C<sub>1</sub>-C<sub>10</sub> fluorinated alkyl, ~~C<sub>1</sub>-C<sub>10</sub> fluorinated alkenyl, or~~  
C<sub>1</sub>-C<sub>10</sub> fluorinated oxyalkyl, ~~or C<sub>1</sub>-C<sub>10</sub> fluorinated oxyalkenyl.~~

No new matter has been added by new Claim 23.

### REJECTIONS UNDER 35 U.S.C. § 102

Claim 15 was rejected under 35. U.S.C. § 102(b) as being anticipated by U.S. Patent 5,730,922 ("*Babb*"). Applicants submit that *Babb* does not teach or suggest the composition of Claim 15 which recites a composition comprising an *active material* and one of the recited *compounds* (not a polymer).

In particular, *Babb* does not disclose his monomer in combination with an active material. While disclosing the use of certain monomers having two perfluorovinyl groups, it is the *Babb polymer* (having more than one perfluorocyclobutane group), not the monomer, that is combined with any other ingredient for use in the laminate composite. See, e.g., *Babb* at col. 1 lines 65 to col. 2, lines 5.

The specific areas cited to in *Babb* by the October 20, 2005, Office communication do not change the conclusion that *Babb* is not combining a monomer with an active ingredient, as recited in Claim 15. Applicants respectfully submit that this rejection should be withdrawn.

Claim 23 is provided and is directed to deleting the alkenyl groups from the X as recited in the compound of Claim 15. This deletion alters the compound recited so as it no longer reads on any of the monomer disclosed in *Babb*. No new issues of examination are presented by new Claim 23 and its allowance is respectfully requested.

Application No.: 10/669403  
Docket No.: UC0315USNA

Page 7

**CONCLUSION**

In view of the foregoing amendment and discussion, Applicants respectfully submit that the above referenced application is in condition for allowance and a notice of allowance is earnestly requested, for Claims 15, 22, and 23.

Respectfully submitted,



MARY ANN CAPRIA  
ATTORNEY FOR APPLICANTS

Registration No.: 32,659

Telephone: (302) 992-3749

Facsimile: (302) 892-7949

Dated: \_\_\_\_\_

1/20/2006